Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Mirion Technologies Inc (MIR) delivers critical radiation safety solutions for nuclear energy, healthcare, and global security markets. This news hub provides investors and industry professionals with essential updates on the company developments shaping radiation detection technologies.
Access timely reports covering earnings announcements, product innovations, strategic partnerships, and regulatory milestones. Our curated collection features press releases and analysis on Mirion's Nuclear & Safety segment advancements and Medical division breakthroughs in cancer treatment safety.
Key updates include radiation monitoring system launches, international expansion efforts, and R&D initiatives addressing emerging nuclear safety challenges. Bookmark this page for structured access to operational updates from Mirion's global facilities and executive leadership commentary.
For stakeholders tracking radiation protection technologies, this resource offers comprehensive monitoring of Mirion's progress in dosimetry systems, environmental monitoring solutions, and medical radiation processing advancements. Return regularly for verified updates maintaining compliance with financial disclosure standards.
Mirion Technologies (NYSE: MIR) reported strong Q2 2025 financial results, with revenue increasing 7.6% to $222.9 million. The company achieved a significant turnaround with GAAP net income of $8.5 million, compared to a $12.0 million loss in Q2 2024. Adjusted EBITDA grew 4.9% to $51.2 million.
Following these results, Mirion raised its 2025 guidance, now projecting revenue growth of 7.0% - 9.0% (up from 5.0% - 7.0%) and adjusted EBITDA of $223-233 million. The company also completed strategic initiatives including a $400 million convertible notes offering, Term Loan B refinancing, and the acquisition of Certrec to expand its nuclear power services.
The company maintains strong positioning in nuclear power and cancer care markets, with management expressing confidence in capturing favorable market trends despite some end-market adjustments in Labs & Research and Dosimetry segments.Mirion (NYSE: MIR) has announced the acquisition of Certrec, a leading regulatory compliance and digital integration solutions provider for the energy industry, for $81 million plus equity incentives. The deal represents a 16.9x EV/2025E EBITDA multiple.
Certrec, based in Fort Worth, TX, has been serving power-generating facilities since 1988, with its solutions currently employed by every US nuclear reactor facility and over 80 entities across North America. The company specializes in regulatory compliance management with the Nuclear Regulatory Commission (NRC) and North American Electric Reliability Corporation (NERC).
The acquisition will strengthen Mirion's Nuclear & Safety group, enhancing its digital ecosystem and expanding its offerings in the nuclear power market.
Mirion (NYSE: MIR) has scheduled its second quarter 2025 financial results release for Thursday, July 31, 2025, after market close. The company will host a conference call to discuss the results on Friday, August 1, 2025, at 10:00 am ET.
Investors can access the call through two dial-in numbers: 1-877-407-9208 (domestic) or 1-201-493-6784 (international). A live webcast will be available on Mirion's investor relations website. A replay will be accessible until August 15, 2025, using the access code 13754545.
[]Mirion Technologies (NYSE: MIR) and Westinghouse Electric Company have formed a strategic partnership to provide digital Ex-core Nuclear Instrumentation Systems based on Mirion's proTK product line. The collaboration aims to upgrade existing analog neutron flux monitoring systems in nuclear power plants.
The digital upgrade solution, offered exclusively through Westinghouse for Westinghouse and Combustion Engineering designed PWRs worldwide, will replace outdated equipment from the 1960s. Mirion's proTK technology has demonstrated reliability with over 400 drawers implemented globally, accumulating more than 4000 operating years of performance across nuclear facilities.
Mirion Technologies reported strong Q1 2025 financial results, with revenues increasing 4.9% to $202.0 million. The company achieved a significant turnaround, posting a GAAP net income of $0.4 million compared to a $26.5 million loss in Q1 2024.
Key highlights include:
- Adjusted EBITDA rose 18% to $46.7 million
- Adjusted earnings per share improved to $0.10 from $0.06
- Total orders increased 11.5% to $203 million
The company updated its 2025 guidance, projecting revenue growth of 5.0-7.0% and organic revenue growth of 5.5-7.5%. Despite new tariff impacts and U.S. government funding reductions, Mirion reaffirmed its Adjusted EBITDA target of $215-230 million and Adjusted EPS guidance of $0.45-$0.50 per share.
Mirion Technologies (NYSE: MIR) has scheduled its first quarter 2025 financial results release for Tuesday, April 29, 2025, after market close. The company will host a conference call on Wednesday, April 30, 2025, at 11:00 am ET to discuss the quarterly performance.
Investors can join the earnings call by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international). A live webcast will be available on the company's investor relations website. A replay of the call will be accessible until May 14, 2025, via phone using access code 13753466 or through Mirion's IR website.
Mirion Technologies (NYSE: MIR) has launched version 1.2 of its Apex-Guard gamma spectroscopy software, enhancing quality control in radiopharmaceutical production. The updated software introduces a patent-pending algorithm for Radionuclidic purity measurements, supporting compliance with FDA regulations.
The release comes amid rapid expansion in the radiopharmaceutical sector, with over 100 drugs in Phase I or further clinical development. The software builds upon Mirion's Genie™ and Apex-Gamma™ platforms, offering advanced controls, security, and audit features. It integrates with BioTrax QMS®, an electronic quality management system from ec2 Software, a Mirion Medical Company.
This enhancement aims to streamline quality management processes and ensure compliance in radioisotope production, particularly important for cancer care applications.
Mirion Technologies (NYSE: MIR) has secured contracts to provide critical systems for TerraPower's Natrium Reactor Demonstration Project in Wyoming, the first commercial advanced nuclear power plant in the U.S. The project, a public-private partnership between TerraPower and the U.S. Department of Energy, will implement Natrium technology combining a sodium-cooled fast reactor with molten salt energy storage.
Mirion will deliver two key systems:
- Radiation Monitoring System (RMS) featuring area, effluent, and process radiation monitors for continuous plant safety monitoring
- Nuclear Instrumentation System (XIS) for detecting reactor power levels
The contracts position Mirion to support innovative nuclear technologies, including small and advanced modular reactors, contributing to meeting modern energy demands with safe, sustainable nuclear power.
Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, has announced its membership in two major nuclear industry organizations. The company has joined the Nuclear Energy Institute (NEI) and enhanced its partnership with the American Nuclear Society (ANS) as a Trustees of Nuclear partner.
Through NEI membership, Mirion will participate in policy discussions shaping the nuclear industry and advocate for nuclear energy growth policies. As an ANS Trustee of Nuclear, the company will serve on its leadership council. CEO Thomas Logan emphasized Mirion's unique position across the nuclear landscape and its commitment to advancing the industry through these strategic partnerships.
FAQ
What is the current stock price of Mirion Technologies (MIR)?
What is the market cap of Mirion Technologies (MIR)?
